)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Marimed
Marimed (MRMD) investor relations material
Marimed Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary12 Nov, 2026
Executive summary
Record Q3 revenue of $44.227M, up 5.5% QoQ and 8.5% YoY; Adjusted EBITDA rose 18% sequentially to $4.657M, its 27th consecutive positive quarter.
Wholesale and retail growth, brand share gains, loyalty engagement and positive operating cash flow supported results amid pricing pressure.
Financial highlights
Q3 revenue was $44.227M versus $40.764M a year ago; nine-month revenue was $125.633M versus $118.176M.
Q3 GAAP net loss was $3.487M and adjusted non-GAAP net loss was $2.252M; GAAP operating income was $1.221M.
Q3 GAAP gross margin was 38.8%, and non-GAAP gross margin was 40.0%, down from 41.4% a year ago.
Income tax provision was $2.743M despite a $0.744M pretax loss; interest expense was $2M.
Q3 operating cash flow was $3.5M versus $2.7M a year ago; nine-month operating cash flow was $7.240M.
Outlook and guidance
No formal Q4 guidance; priorities include leveraging brands, production capacity and operating efficiencies to grow market share, open accounts and invest in the business.
New York processing kitchen remains on schedule for H1 2027; licensing and third-party distribution aim to extend brand reach with limited capital.
Growth strategy emphasizes brand innovation, edibles and beverages, broader distribution, licensing, MSA expansion and high-ROIC opportunities.
Pricing compression, especially in Massachusetts, and inflation-driven production costs may pressure margins and profitability.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Marimed
- Shareholders will vote on a reverse stock split to support potential uplisting and address share price.MRMD
Proxy filing - Shareholders will vote on a reverse stock split aimed at meeting major exchange listing requirements.MRMDProxy filing
- Q2 2026 revenue rose 6% to $41.9M, with strong retail, wholesale, and positive cash flow.MRMDQ2 2026
- Board re-elections and auditor approval passed; management optimistic on regulatory and market outlook.MRMDAGM 2026
- Revenue up 4.2% to $39.5M, adjusted EBITDA improved, and liquidity enhanced by restructuring.MRMDQ1 2026
- Shareholders will vote on director elections and auditor approval, with robust governance and compensation disclosures.MRMDProxy filing
- 2025 revenue rose 7% to $159.8M, driven by 11% wholesale growth and improved liquidity.MRMDQ4 2025
- Q3 2024 revenue up 4.6% to $40.6M, net loss narrows, and wholesale outperforms.MRMDQ3 2024
- Q2 revenue up 11% to $40.4M; margin pressure persists but 2024 growth targets reaffirmed.MRMDQ2 2024
Next Marimed earnings date
Q4 20263 Mar, 2027
Marimed
Next Marimed earnings date
Q4 20263 Mar, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
MariMed, Inc. operates as an integrated cannabis company that develops and licenses production and dispensing of medicinal and recreational cannabis, and owns the largest cannabis dispensing chain in the United States. Through its subsidiaries, the company produces and sells cannabis-infused products, including flower, concentrates, vaporizer cartridges used in e-cigarettes and packaging materials to producers of vape cartridges.
It provides training on topics related to cultivation techniques and strategic launch of products; and provides leasing support as well as on-site training programs for dispensary employees. The company also offers advisory services to help clients establish marijuana cultivation facilities; develop brands; build facilities or execute mergers and acquisitions.